
Alberta Cappelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7727830/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology, 2011, 54, 868-878.	3.6	550
2	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology, 2011, 53, 1580-1589.	3.6	229
3	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1927-1933.e2.	2.4	108
4	Yttriumâ€90 radioembolization vs sorafenib for intermediateâ€locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver International, 2015, 35, 1036-1047.	1.9	94
5	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplantation, 2010, 16, 658-667.	1.3	93
6	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 79-86.	1.8	83
7	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 753-761.	1.8	82
8	A metaâ€analysis of single <scp>HCV</scp> â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp> â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	1.9	70
9	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	1.9	70
10	Refining prognosis after transâ€arterial chemoâ€embolization for hepatocellular carcinoma. Liver International, 2016, 36, 729-736.	1.9	62
11	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. British Journal of Cancer, 2016, 115, 297-302.	2.9	58
12	Computed tomography-guided percutaneous abscess drainage in coloproctology: review of the literature. Techniques in Coloproctology, 2007, 11, 197-208.	0.8	56
13	CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Techniques in Coloproctology, 2006, 10, 99-105.	0.8	55
14	Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. British Journal of Cancer, 2014, 111, 667-673.	2.9	51
15	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World Journal of Hepatology, 2015, 7, 738.	0.8	48
16	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. Journal of Personalized Medicine, 2021, 11, 1041.	1.1	48
17	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Digestive and Liver Disease, 2016, 48, 798-805.	0.4	46
18	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	1.9	46

ALBERTA CAPPELLI

#	Article	IF	CITATIONS
19	Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma—a Systemic Review and Meta-Analysis. CardioVascular and Interventional Radiology, 2021, 44, 728-738.	0.9	44
20	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. CardioVascular and Interventional Radiology, 2020, 43, 1305-1314.	0.9	41
21	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. Inflammatory Bowel Diseases, 2020, 26, 321-330.	0.9	38
22	Improving patient selection for selective internal radiation therapy of intraâ€hepatic cholangiocarcinoma: A metaâ€regression study. Liver International, 2017, 37, 1056-1064.	1.9	35
23	Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. European Radiology, 2020, 30, 4534-4544.	2.3	34
24	Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman. Digestive and Liver Disease, 2008, 40, 387-390.	0.4	29
25	Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies. Liver Cancer, 2016, 5, 303-311.	4.2	23
26	Average treatment effect of hepatic resection <i>versus</i> locoregional therapies for hepatocellular carcinoma. British Journal of Surgery, 2017, 104, 1704-1712.	0.1	21
27	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate–advanced hepatocellular carcinoma. Future Oncology, 2015, 11, 3133-3142.	1.1	20
28	Years of life that could be saved from prevention of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2016, 43, 814-824.	1.9	20
29	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scandinavian Journal of Gastroenterology, 2012, 47, 1494-1500.	0.6	19
30	Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. Radiologia Medica, 2015, 120, 767-776.	4.7	19
31	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1721-1730.	3.3	18
32	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Scientific Reports, 2019, 9, 3781.	1.6	18
33	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	1.7	18
34	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. Journal of Hepatocellular Carcinoma, 2014, 1, 163.	1.8	15
35	Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncology, 2017, 13, 1301-1310.	1.1	15
36	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transplantation, 2021, 27, 1758-1766.	1.3	15

ALBERTA CAPPELLI

#	Article	IF	CITATIONS
37	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1048-1059.	0.9	14
38	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.4	10
39	FDG PET/CT for bone and soft-tissue biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1333-1334.	3.3	10
40	Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer, 2021, 10, 522-534.	4.2	10
41	Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Journal of Hepatology, 2018, 69, 259-260.	1.8	9
42	First Case of 2 Intraductal Papillary Mucinous Tumors of Both Ventral and Dorsal Ducts in Pancreas Divisum. Pancreas, 2010, 39, 110-111.	0.5	8
43	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3058-3065.	3.3	8
44	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 661-668.	3.3	7
45	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. Crohn's & Colitis 360, 2020, 2, .	0.5	7
46	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70ÂYears of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. CardioVascular and Interventional Radiology, 2020, 43, 1015-1024.	0.9	6
47	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	1.3	4
48	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability CanÂOptimize Clinical Outcome. Ultraschall in Der Medizin, 2017, 38, 515-522.	0.8	3
49	Portal Hypertensive Biliopathy in Adult Patients: Findings and Interventional Radiologic Treatment—A Single-Center Experience. Seminars in Liver Disease, 2019, 39, 502-512.	1.8	3
50	Scar Pregnancy and Extrauterine Implants. Seminars in Ultrasound, CT and MRI, 2021, 42, 46-55.	0.7	3
51	Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	3
52	Balloon-assisted coil embolization (BACE) of a wide-necked aneurysm of the inferior pancreaticoduodenal artery. CVIR Endovascular, 2020, 3, 62.	0.4	3
53	Reply to: "Sorafenib or ⁹⁰ Y loaded resin microsphere radioembolization for locallyâ€ødvanced hepatocellular carcinoma, what should we trust?― Liver International, 2015, 35, 1780-1781.	1.9	2
54	Outcomes following percutaneous treatment of biliary stones. Hpb, 2019, 21, 1057-1063.	0.1	2

ALBERTA CAPPELLI

#	Article	IF	CITATIONS
55	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	0.2	2
56	High-flow priapism after T-shunt and tunneling in a patient with ischemic priapism. Turkish Journal of Urology, 2020, 46, 488-491.	1.3	2
57	Reply to "Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis― CardioVascular and Interventional Radiology, 2021, 44, 1135-1136.	0.9	1
58	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	4.2	1
59	Routine blood tests? Helping you live(r) longer!. Lancet, The, 2011, 378, 2048.	6.3	0
60	Young Women With Acute Lower Gastrointestinal Bleeding. Annals of Emergency Medicine, 2016, 68, e55-e56.	0.3	0
61	Reply to External validation of an individual prognostic calculator after transâ€arterial chemoâ€embolization for hepatocellular carcinoma. Liver International, 2016, 36, 1232-1232.	1.9	0
62	Trans-arterial embolization for hepatocellular carcinoma: with or without epidoxorubicin?. Translational Cancer Research, 2016, 5, S208-S211.	0.4	0
63	Transarterial Chemoembolisation and Combined Therapy. Medical Radiology, 2021, , 283-317.	0.0	0
64	Percutaneous abdomino-pelvic abscess drainage in complicated Crohn's disease. Annals of Clinical Gastroenterology and Hepatology, 2020, 4, 045-051.	0.1	0